中国免疫学杂志
中國免疫學雜誌
중국면역학잡지
CHINESE JOURNAL OF IMMUNOLOGY
2015年
2期
225-229
,共5页
胶质瘤%MAGE-E1%实时定量PCR%肿瘤免疫治疗
膠質瘤%MAGE-E1%實時定量PCR%腫瘤免疫治療
효질류%MAGE-E1%실시정량PCR%종류면역치료
Glioma%MAGE-E1%Quantitative Real-Time PCR%Tumor immunotherapy
目的:了解MAGE-E1 mRNA在胶质瘤中的表达,探讨将它用于胶质瘤免疫治疗的可能性。方法:建立实时定量PCR方法,检测47例人胶质瘤及14例正常脑组织中MAGE-E1,管家基因HPRT1作为内参,以MAGE-E1/HPRT1值计算MAGE-E1 mRNA表达量,并对MAGE-E1 mRNA表达与临床指标的关系进行分析。结果:在正常脑组织及胶质瘤中, MAGE-E1高度表达率分别为7.1%和66.0%,两者比较具有统计学差异( P<0.05)。 MAGE-E1 mRNA的表达与病人性别、年龄、病理类型和级别无关。结论:MAGE-E1 mRNA在胶质瘤中水平较高,提示MAGE-E1可能成为胶质瘤免疫治疗的候选靶抗原。
目的:瞭解MAGE-E1 mRNA在膠質瘤中的錶達,探討將它用于膠質瘤免疫治療的可能性。方法:建立實時定量PCR方法,檢測47例人膠質瘤及14例正常腦組織中MAGE-E1,管傢基因HPRT1作為內參,以MAGE-E1/HPRT1值計算MAGE-E1 mRNA錶達量,併對MAGE-E1 mRNA錶達與臨床指標的關繫進行分析。結果:在正常腦組織及膠質瘤中, MAGE-E1高度錶達率分彆為7.1%和66.0%,兩者比較具有統計學差異( P<0.05)。 MAGE-E1 mRNA的錶達與病人性彆、年齡、病理類型和級彆無關。結論:MAGE-E1 mRNA在膠質瘤中水平較高,提示MAGE-E1可能成為膠質瘤免疫治療的候選靶抗原。
목적:료해MAGE-E1 mRNA재효질류중적표체,탐토장타용우효질류면역치료적가능성。방법:건립실시정량PCR방법,검측47례인효질류급14례정상뇌조직중MAGE-E1,관가기인HPRT1작위내삼,이MAGE-E1/HPRT1치계산MAGE-E1 mRNA표체량,병대MAGE-E1 mRNA표체여림상지표적관계진행분석。결과:재정상뇌조직급효질류중, MAGE-E1고도표체솔분별위7.1%화66.0%,량자비교구유통계학차이( P<0.05)。 MAGE-E1 mRNA적표체여병인성별、년령、병리류형화급별무관。결론:MAGE-E1 mRNA재효질류중수평교고,제시MAGE-E1가능성위효질류면역치료적후선파항원。
Objective:To investigate the quantitative expression of Melanoma-associated antigen MAGE-E1 mRNA in glioma, and explore its potential for immunotherapy in glioma.Methods:To establish a quantitative real-time polymerase chain reaction ( qRT-PCR) method to quantitatively determine MAGE-E1 mRNA in glioma.A total of 47 human glioma and 14 normal brain tissue specimens were analyzed.MAGE-E1 mRNA was normalized to HPRT1, a housekeeping gene.MAGE-E1/HPRT1 was used to evaluate the expression level of MAGE-E1 mRNA.Results:High-level expression of MAGE-E1 was observed in 7.1%of normal brain and 66.0%glioma tissues,which shown significant difference with P<0.05.There was irrelevant between the expression of MAGE-E1 mRNA and clinicopathogical parameters ,such as gender ,age,histological subtype and grade.Conclusion:With higher expression of MAGE-E1 in glioma tissues,it might be a potential target for immunotherapy of glioma.